ARTICLE
17 June 2026

ERISA Industry Committee Supports PBM Kickback Prohibition Act Before House

HB
Hall Benefits Law

Contributor

Strategically designed, legally compliant benefit plans are the cornerstone of long-term business stability and growth. As such, HBL provides comprehensive legal guidance on benefits in M&A, ESOPs, executive compensation, health and welfare benefits, retirement plans, and ERISA litigation matters. Responsive, relationship-driven counsel is the calling card of the Firm.
The ERISA Industry Committee has voiced strong support for proposed legislation that would prohibit pharmacy benefit managers from paying kickbacks to brokers and consultants.
United States Employment and HR
Hall Benefits Law are most popular:
  • within Consumer Protection topic(s)

James Gelfand, CEO of the ERISA Industry Committee (ERIC), a major employer group, recently expressed support for the PBM Kickback Prohibition Act at a hearing before the House Education & the Workforce Committee’s health subcommittee. Rep. Rick Allen, R-Ga, is the sponsor for the Act, which would prevent pharmacy benefit managers (PBMs) from paying referral fees, or kickbacks, whether the referral comes from a benefits broker, consultant, advisor, or any other individual. 

In expressing his support for the Act, Gelfand pointed out that the bill would restore trust in the health insurance industry and create more affordable healthcare for workers. Although brokers and consultants provide an invaluable service and unparalleled expertise, he noted, trust in these individuals is paramount. 

Some witnesses recounted the “pay-to-play” model that has allowed consultants assisting group health plans to obtain PBM contracts while receiving kickbacks from PBMs bidding on contracts with insurers. For instance, one consultant stated that a common health plan request for proposal from PBMs asked whether they would pay the broker $50,000 per year for the duration of the contract. Typically, the group health plan would never see bids from PBMs not willing to participate in the racket. 

In contrast, the CEO of the Pharmaceutical Care Management Association, a PBM group, emphasized the role that PBMs play in maintaining lower drug prices and offering critical services. He claimed that the witnesses testifying at the hearings will further prejudice listeners about the PBM industry. The CEO also pointed out that a new PBM law already requires full disclosure of any fees paid to brokers and consultants, which are not kickbacks. He characterized PBMs as more transparent than other players in the prescription drug supply chain and remarked that the Act would do nothing to reduce health care costs for consumers.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More